Bhat Sujatha, Gunawardana Dushan Uvindu, Boparai Delisha Kaur, Bamunusinghe Tharinya Kasundie, Krishanth Kavin, Premakrishna Aarabi, Narasimhaswamy Nagalakshmi
Division of Microbiology, Department of Basic Medical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Melaka Manipal Medical College (Manipal Campus), Manipal Academy of Higher Education, Manipal, Karnataka, India.
Antimicrob Steward Healthc Epidemiol. 2024 Nov 14;4(1):e206. doi: 10.1017/ash.2024.419. eCollection 2024.
During the past several decades, enterococci are emerging as an important cause of healthcare-associated infections. They have developed resistance to various antimicrobials previously used for the treatment of urinary tract infections (UTIs). This study was aimed to determine the prevalence of among urinary tract-infected patients in a tertiary care hospital, in Karnataka, India.
We have analyzed 4341 culture-positive urine samples received by microbiology laboratory during the year 2021. The bacterial identification was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The antibiotic sensitivity was tested by automated VITEK-2® COMPACT (bioMérieux) system.
Among 4341 culture-positive samples, Enterococcal species were isolated from 159 samples. A total of 64.7% of the isolates were identified as and 28.3% of the strains as . All the enterococci were sensitive to linezolid, teicoplanin, and vancomycin, whereas 59.1%, 30.9%, and 23.3% of the strains exhibited resistance to high-level gentamicin, benzylpenicillin, and nitrofurantoin, respectively. 33.67 % of the isolates were identified as multidrug-resistant (MDR) strains as they exhibited resistance to high-level gentamicin, benzylpenicillin, and nitrofurantoin.
Our study shows the prevalence of and high-level gentamicin-resistant enterococcal strains. The MDR pattern of enterococci requires careful consideration of antimicrobial therapy to treat UTIs. The reserved drugs such as linezolid, vancomycin, and teicoplanin should be cautiously used for the treatment of enterococcal UTI.
在过去几十年中,肠球菌正逐渐成为医疗保健相关感染的重要原因。它们已对先前用于治疗尿路感染(UTIs)的各种抗菌药物产生耐药性。本研究旨在确定印度卡纳塔克邦一家三级护理医院中尿路感染患者中肠球菌的流行情况。
我们分析了微生物实验室在2021年收到的4341份培养阳性尿液样本。通过基质辅助激光解吸电离飞行时间质谱法进行细菌鉴定。通过自动化VITEK-2® COMPACT(生物梅里埃)系统检测抗生素敏感性。
在4341份培养阳性样本中,从159份样本中分离出肠球菌属。共64.7%的分离株被鉴定为粪肠球菌,28.3%的菌株为屎肠球菌。所有肠球菌对利奈唑胺、替考拉宁和万古霉素敏感,而分别有59.1%、30.9%和23.3%的菌株对高水平庆大霉素、苄青霉素和呋喃妥因耐药。33.67%的分离株被鉴定为多重耐药(MDR)菌株,因为它们对高水平庆大霉素、苄青霉素和呋喃妥因耐药。
我们的研究显示了粪肠球菌和高水平庆大霉素耐药肠球菌菌株的流行情况。肠球菌的多重耐药模式需要在治疗尿路感染时仔细考虑抗菌治疗。利奈唑胺、万古霉素和替考拉宁等储备药物应谨慎用于治疗肠球菌性尿路感染。